

# Relapsed and Refractory CD5-Expressing T Cell Lymphomas - Pipeline Insight, 2022

<https://marketpublishers.com/r/R54C0FFEDF07EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: R54C0FFEDF07EN

## Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Relapsed and Refractory CD5-Expressing T Cell Lymphomas - Pipeline Insight, 2022" report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Relapsed and Refractory CD5-Expressing T Cell Lymphomas pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Relapsed and Refractory CD5-Expressing T Cell Lymphomas Understanding

#### Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Overview

Relapsed and Refractory CD5-Expressing T Cell Lymphomas refers to lymphoma that reappears or grows again after a period of remission or the lymphoma that does not respond to available therapy treatment (meaning that the cancer cells continue to grow). There is no consensus exists on the best therapeutic strategy for relapsed/refractory Peripheral T-Cell Lymphoma (PTCL). CD5 is one of the most common surface markers of malignant T cells, expressed in around 80% of TALLs (T cell acute lymphoblastic leukemia) and T<sub>H</sub> cell lymphomas. CD5 as a receptor regulates T<sub>H</sub> cell development and

function, acting as a negative regulator of TCR $\alpha$ CD3 signaling. CD5+ T cell lymphomas are a subset of lymphomas that are positive for the surface protein CD5. CD5 is a T cell, B1-a cell, and B-CLL receptor first described over 30 years ago that has been used as surface marker to identify both human and murine cell populations. CD5 is a potentially good target for a T $\alpha$ cell based CAR therapy.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Relapsed and Refractory CD5-Expressing T Cell Lymphomas R&D. The therapies under development are focused on novel approaches for Relapsed and Refractory CD5-Expressing T Cell Lymphomas.

## Relapsed and Refractory CD5-Expressing T Cell Lymphomas Emerging Drugs Chapters

This segment of the Relapsed and Refractory CD5-Expressing T Cell Lymphomas report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Relapsed and Refractory CD5-Expressing T Cell Lymphomas Emerging Drugs

### Anti-CD5 CAR T-cell therapy: iCell Gene Therapeutics

Anti-CD5 CAR T cells are transduced cells in a lentiviral vector to express CD5 chimeric receptor domain on T cells. CAR engineered cells express a single-chain variable fragments (ScFvs) which target CD5 on T cell malignancies. In this engineered cells, the scFV (single-chain variable fragment) nucleotide sequence of anti-CD5 was subcloned into a CAR lentiviral vector. The USFDA has granted Orphan Drug Designation to Anti-CD5 CAR T cells for Peripheral T-cell Lymphoma.

### MT-101: Myeloid Therapeutics

MT-101 is a potential treatment of Relapsed and Refractory CD5-Expressing T Cell

Lymphomas. Refractory PTCL is a lethal disease with limited treatment options that until now has not benefited from innovations in cell therapy. In vitro and in vivo studies show MT-101 demonstrated meaningful anti-tumor activity.

Further product details are provided in the report.....

## Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Therapeutic Assessment

This segment of the report provides insights about the different Relapsed and Refractory CD5-Expressing T Cell Lymphomas drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Relapsed and Refractory CD5-Expressing T Cell Lymphomas

There are approx. 2+ key companies which are developing the Relapsed and Refractory CD5-Expressing T Cell Lymphomas. The companies which have their Relapsed and Refractory CD5-Expressing T Cell Lymphomas drug candidates in the most advanced stage, i.e. Phase I include, iCell Gene Therapeutics.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Relapsed and Refractory CD5-Expressing T Cell Lymphomas pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

## Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsed and Refractory CD5-Expressing T Cell Lymphomas therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsed and Refractory CD5-Expressing T Cell Lymphomas drugs.

## Relapsed and Refractory CD5-Expressing T Cell Lymphomas Report Insights

- Relapsed and Refractory CD5-Expressing T Cell Lymphomas Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

## Relapsed and Refractory CD5-Expressing T Cell Lymphomas Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

## Key Questions

### Current Scenario and Emerging Therapies:

How many companies are developing Relapsed and Refractory CD5-Expressing T Cell Lymphomas drugs?

How many Relapsed and Refractory CD5-Expressing T Cell Lymphomas drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Relapsed and Refractory CD5-Expressing T Cell Lymphomas?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Relapsed and Refractory CD5-Expressing T Cell Lymphomas therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Relapsed and Refractory CD5-Expressing T Cell Lymphomas and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Myeloid Therapeutics

iCell Gene Therapeutics

## Key Products

MT-101

## Anti-CD5 CAR T-cell therapy

## Contents

Introduction

Executive Summary

Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Relapsed and Refractory CD5-Expressing T Cell Lymphomas – DelveInsight's

Analytical Perspective

In-depth Commercial Assessment

Relapsed and Refractory CD5-Expressing T Cell Lymphomas companies' collaborations, Licensing, Acquisition -Deal Value Trends

Relapsed and Refractory CD5-Expressing T Cell Lymphomas Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)



- Comparative Analysis
- Anti-CD5 CAR T-cell therapy: iCell Gene Therapeutics
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products
  - Comparative Analysis
- Drug name: Company name
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Inactive Products
  - Comparative Analysis
- Relapsed and Refractory CD5-Expressing T Cell Lymphomas Key Companies
- Relapsed and Refractory CD5-Expressing T Cell Lymphomas Key Products
- Relapsed and Refractory CD5-Expressing T Cell Lymphomas- Unmet Needs
- Relapsed and Refractory CD5-Expressing T Cell Lymphomas- Market Drivers and Barriers
- Relapsed and Refractory CD5-Expressing T Cell Lymphomas- Future Perspectives and Conclusion
- Relapsed and Refractory CD5-Expressing T Cell Lymphomas Analyst Views
- Relapsed and Refractory CD5-Expressing T Cell Lymphomas Key Companies
- Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Relapsed and Refractory CD5-Expressing T Cell Lymphomas

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Relapsed and Refractory CD5-Expressing T Cell Lymphomas

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Relapsed and Refractory CD5-Expressing T Cell Lymphomas - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/R54C0FFEDF07EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R54C0FFEDF07EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970